Literature DB >> 33747909

Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer.

Yang Hong1, Jiahui Si1, Jie Zhang2, Ying Xiong1, Jianzhi Zhang1, Peter Ping Lin3, Jian Fang2, Yue Yang1, Chao Lv1, Yuanyuan Ma1.   

Abstract

OBJECTIVE: The size distribution of circulating aneuploid cells (CACs) and its clinical significance were investigated in resectable non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: A total of 50 patients with resectable NSCLC were enrolled in this study. Blood samples (50 pre-surgery and 35 post-surgery) were collected and used for the detection of CAC chromosome 8 heteroploidy through the subtraction enrichment and immunostaining fluorescence in situ hybridization (SE-iFISH) method.
RESULTS: Less than 20% small cell size and more than 80% large cell size CACs were detected. Karyotypes, including triploid, tetraploid, and multiploid, had varying distributions. The triploid subtype accounted for the majority of small cell size CACs, whereas the multiploid subtype accounted for the majority of large cell size CACs. We found that total small cell size and triploid small cell size CACs, but not large cell size CACs, derived from pre-surgery samples, were associated with shorter disease-free survival. Moreover, total small cell size and triploid small cell size CACs were associated with higher TNM stage and recurrence. Nevertheless, the variation between pre- and post-surgery CACs was not related to survival among patients with resectable NSCLC.
CONCLUSIONS: Pre-surgery small cell size CACs, especially the triploid subtype, could be regarded as a potential prognostic biomarker for patients with resectable NSCLC.
Copyright © 2021 Hong, Si, Zhang, Xiong, Zhang, Lin, Fang, Yang, Lv and Ma.

Entities:  

Keywords:  biomarker; circulating aneuploid cells; non-small cell lung cancer; prognosis; resection

Year:  2021        PMID: 33747909      PMCID: PMC7968455          DOI: 10.3389/fonc.2021.590952

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  49 in total

Review 1.  Causes and consequences of aneuploidy in cancer.

Authors:  David J Gordon; Benjamin Resio; David Pellman
Journal:  Nat Rev Genet       Date:  2012-01-24       Impact factor: 53.242

2.  Circulating Tumor Cells in Patients Undergoing Resection of Colorectal Cancer Liver Metastases. Clinical Utility for Long-Term Outcome: A Prospective Trial.

Authors:  Virginia Arrazubi; Elena Mata; María Luisa Antelo; Antonio Tarifa; Javier Herrera; Cruz Zazpe; Lucía Teijeira; Antonio Viudez; Javier Suárez; Irene Hernández; Ruth Vera
Journal:  Ann Surg Oncol       Date:  2019-06-17       Impact factor: 5.344

3.  Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery.

Authors:  Maria T Sandri; Laura Zorzino; Maria C Cassatella; Fabio Bassi; Alberto Luini; Chiara Casadio; Edoardo Botteri; Nicole Rotmensz; Laura Adamoli; Franco Nolè
Journal:  Ann Surg Oncol       Date:  2010-02-05       Impact factor: 5.344

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.

Authors:  O Juan; J Vidal; R Gisbert; J Muñoz; S Maciá; J Gómez-Codina
Journal:  Clin Transl Oncol       Date:  2013-11-12       Impact factor: 3.405

Review 6.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

7.  Clinical significance of phenotyping and karyotyping of circulating tumor cells in patients with advanced gastric cancer.

Authors:  Yilin Li; Xiaotian Zhang; Sai Ge; Jing Gao; Jifang Gong; Ming Lu; Qiyue Zhang; Yanshuo Cao; Daisy Dandan Wang; Peter Ping Lin; Lin Shen
Journal:  Oncotarget       Date:  2014-08-30

8.  Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework.

Authors:  Ida Netterberg; Mats O Karlsson; Leon W M M Terstappen; Miriam Koopman; Cornelis J A Punt; Lena E Friberg
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

9.  Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization.

Authors:  Yang Gao; Yayun Zhu; Zhenzhen Zhang; Cheng Zhang; Xinyu Huang; Zhou Yuan
Journal:  J Exp Clin Cancer Res       Date:  2016-04-12

10.  Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells.

Authors:  Peter Ping Lin; Olivier Gires; Daisy Dandan Wang; Linda Li; Hongxia Wang
Journal:  Sci Rep       Date:  2017-08-29       Impact factor: 4.379

View more
  3 in total

1.  Comprehensive Atlas of Circulating Rare Cells Detected by SE-iFISH and Image Scanning Platform in Patients With Various Diseases.

Authors:  Binjie Hu; Yanping Gong; Yulan Wang; Jianzhu Xie; Jin Cheng; Qian Huang
Journal:  Front Oncol       Date:  2022-03-02       Impact factor: 6.244

2.  Case report: Post-therapeutic laryngeal carcinoma patient possessing a high ratio of aneuploid CTECs to CTCs rapidly developed de novo malignancy in pancreas.

Authors:  Jiaoping Mi; Fang Yang; Jiani Liu; Mingyang Liu; Alexander Y Lin; Daisy Dandan Wang; Peter Ping Lin; Qi Zeng
Journal:  Front Oncol       Date:  2022-09-12       Impact factor: 5.738

3.  Nonhematogenic circulating aneuploid cells confer inferior prognosis and therapeutic resistance in gliomas.

Authors:  Mingxiao Li; Faliang Gao; Xiaohui Ren; Gehong Dong; Hongyan Chen; Alexander Y Lin; Daisy Dandan Wang; Mingyang Liu; Peter Ping Lin; Shaoping Shen; Haihui Jiang; Chuanwei Yang; Xiaokang Zhang; Xuzhe Zhao; Qinghui Zhu; Ming Li; Yong Cui; Song Lin
Journal:  Cancer Sci       Date:  2022-08-08       Impact factor: 6.518

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.